Active Ingredient(s): Doravirine + Lamivudine + Tenofovir Disoproxil Fumarate
FDA Approved: * August 30, 2018
Pharm Company: * MSD MERCK CO
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Delstrigo Overview

Doravirine/lamivudine/tenofovir (brand name Delstrigo) is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[2][4] It contains doravirine, lamivudine, and tenofovir disoproxil.[5][4] In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[5][6][7] References .mw-parser-out...

Read more Delstrigo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Delstrigo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Doravirine + Lamivudine + Tenofovir Disoproxil Fumarate
  • Tablet: 100mg + 300mg + 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Delstrigo: (1 result)

Sorted by National Drug Code
  • 0006-5007 Delstrigo Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Drugs with one or more similar ingredients: (26 results)